Cipla Recalls Azacitidine Injection Vials Due to Sterility Concerns

Plain-English summary

Cipla USA, Inc. is recalling 2,151 vials of Azacitidine for Injection 100 mg/vial. The product is manufactured by Shilpa Medicare Limited in India and distributed nationwide in the United States. The specific lot number is 7S10182A, with an expiration date of September 2021.

The recall was initiated due to Current Good Manufacturing Practice (cGMP) deviations. Specifically, the vials may not be sealed correctly, which could affect the sterility of the medication. This is an FDA Class II recall, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.

Healthcare providers and patients should stop using the affected lot of Azacitidine for Injection. Consumers should check their medication for the lot number 7S10182A and expiration date of 9/2021. If the product matches these details, it should be returned to the pharmacy or contact Cipla for further instructions.

The recalled product

Product

Azacitidine for Injection 100 mg/vial For Subcutaneous and Intravenous Use Only Single-Dose Vial Manufactured by Shilpa Medicare Limited Jadcherla -509301 INDIA Distributed by: Cipla USA, Inc. 10 Independence Blvd, Suite 300 Warren, NJ 07059 NDC 69097-805-40

Manufacturer

CIPLA

Category

Drug — Injectable Medication

Hazard

• sterility
• infection-risk

Affected units

2,151

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Distribution

Related recalls